Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 2/1998

01-06-1998 | ORIGINAL ARTICLE

In vitro schedule-dependent interaction between paclitaxel and SN-38 (the active metabolite of irinotecan) in human carcinoma cell lines

Authors: Yasuhiko Kano, Miyuki Akutsu, Saburo Tsunoda, Koyoshi Mori, Kenichi Suzuki, Ken-Ichi Adachi

Published in: Cancer Chemotherapy and Pharmacology | Issue 2/1998

Login to get access
Metadata
Title
In vitro schedule-dependent interaction between paclitaxel and SN-38 (the active metabolite of irinotecan) in human carcinoma cell lines
Authors
Yasuhiko Kano
Miyuki Akutsu
Saburo Tsunoda
Koyoshi Mori
Kenichi Suzuki
Ken-Ichi Adachi
Publication date
01-06-1998
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 2/1998
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s002800050790

Other articles of this Issue 2/1998

Cancer Chemotherapy and Pharmacology 2/1998 Go to the issue

SHORT COMMUNICATION

Glucocorticoid pretreatment reduces the cytotoxic effects of a variety of DNA-damaging agents on rat tibial growth-plate chondrocytes in vitro

ORIGINAL ARTICLE

Phase I and pharmacokinetic study of d-limonene in patients with advanced cancer

ORIGINAL ARTICLE

Phase I study of oral JM216 given twice daily

ORIGINAL ARTICLE

Time dependency of hematopoietic growth factor coupled to chronotoxicity of carboplatin

ORIGINAL ARTICLE

Phase I study of E7010

ORIGINAL ARTICLE

Molecular characterization of human acute leukemia cell line resistant to ZD9331, a non-polyglutamatable thymidylate synthase inhibitor
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits